Thus, APP might serve as a common therapeutic target against Alzheimer's Disease (AD) and a host of other neurodegenerative diseases characterized by abnormal levels of Aβ and/or Tau. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.